Literature DB >> 31399820

Comparison of Tissue and Blood Concentrations of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy.

Urs Giger-Pabst1,2, Petru Bucur3, Sébastien Roger4, Thomas Albert Falkenstein2, Nicolas Tabchouri3, Alain Le Pape5, Stéphanie Lerondel5, Cédric Demtröder1,2, Ephrem Salamé3, Mehdi Ouaissi6,7.   

Abstract

BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new technology for delivering intraperitoneal chemotherapy. It is generally assumed that with PIPAC, the ratio of peritoneal to systemic drug concentration is superior to liquid hyperthermic intraperitoneal chemotherapy (HIPEC). To date, no direct comparative data are available supporting such an assumption.
MATERIALS AND METHODS: Twelve 65-day-old pigs were randomly separated into three groups of four pigs each, all of which received intraperitoneal chemotherapy using the following administration methods: PIPAC with oxaliplatin 92 mg in 150 ml dextrose 5% (Group 1); PIPAC with electrostatic aerosol precipitation (ePIPAC; Group 2); or laparoscopic HIPEC (L-HIPEC) with oxaliplatin 400 mg in 4 L dextrose 5% at 42 °C (Group 3). Serial blood and peritoneal tissue concentrations of oxaliplatin were determined by spectrometry.
RESULTS: In all three groups, the maximum concentration of oxaliplatin in blood was detected 50-60 min after onset of the chemotherapy experiments, with no significant differences among the three groups (p = 0.7994). Blood oxaliplatin concentrations (0-30 min) were significantly higher in the L-HIPEC group compared with the ePIPAC group (p < 0.05). No difference was found for the overall systemic oxaliplatin absorption (area under the curve). Overall concentrations in the peritoneum were not different among the three groups (p = 0.4725), but were significantly higher in the visceral peritoneum in the PIPAC group (p = 0.0242).
CONCLUSIONS: Blood and tissue concentrations were comparable between all groups; however, depending on the intraperitoneal area examined and the time points of drug delivery, the concentrations differed significantly between the three groups.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31399820     DOI: 10.1245/s10434-019-07695-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

Review 1.  The emergence of pressurized intraperitoneal aerosol chemotherapy as a palliative treatment option for patients with diffuse peritoneal metastases: a narrative review.

Authors:  Robin J Lurvink; Kurt Van der Speeten; Koen P Rovers; Ignace H J T de Hingh
Journal:  J Gastrointest Oncol       Date:  2021-04

2.  Clinical Outcome for Patients Managed with Low-Dose Cisplatin and Doxorubicin Delivered as Pressurized Intraperitoneal Aerosol Chemotherapy for Unresectable Peritoneal Metastases of Gastric Cancer.

Authors:  Rémy Sindayigaya; Can Dogan; Cédric Remy Demtröder; Britta Fischer; Elias Karam; Jonathan Robin Buggisch; Clemens B Tempfer; Thierry Lecomte; Mehdi Ouaissi; Urs Giger-Pabst
Journal:  Ann Surg Oncol       Date:  2021-10-05       Impact factor: 5.344

Review 3.  Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.

Authors:  Megan M Harper; Joseph Kim; Prakash K Pandalai
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

4.  Development and technical validation of an ultrasound nebulizer to deliver intraperitoneal pressurized aerosols in a rat colon cancer peritoneal metastases model.

Authors:  Jonathan R Buggisch; Daniel Göhler; Julien Sobilo; Stéphanie Lerondel; Günther A Rezniczek; Michael Stintz; Andreas Rudolph; Nicolas Tabchouri; Sébastien Roger; Mehdi Ouaissi; Urs Giger-Pabst
Journal:  BMC Cancer       Date:  2022-05-21       Impact factor: 4.638

Review 5.  Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).

Authors:  Giorgi Nadiradze; Philipp Horvath; Yaroslav Sautkin; Rami Archid; Frank-Jürgen Weinreich; Alfred Königsrainer; Marc A Reymond
Journal:  Cancers (Basel)       Date:  2019-12-20       Impact factor: 6.639

6.  Increased Tissue Penetration of Doxorubicin in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) after High-Intensity Ultrasound (HIUS).

Authors:  Veria Khosrawipour; Sören Reinhard; Alice Martino; Tanja Khosrawipour; Mohamed Arafkas; Agata Mikolajczyk
Journal:  Int J Surg Oncol       Date:  2019-12-12

7.  Acute respiratory distress syndrome (ARDS) after pressurized intraperitoneal aerosol chemotherapy with oxaliplatin: a case report.

Authors:  Emilie Thibaudeau; Corinne Brianchon; Jean-Luc Raoul; Frédéric Dumont
Journal:  Pleura Peritoneum       Date:  2021-10-05

8.  Influence of pre-analytical sample preparation on drug concentration measurements in peritoneal tissue: an ex-vivo study.

Authors:  Arianna Castagna; Iaroslav Sautkin; Frank-Jürgen Weinreich; Hannah Heejung Lee; Alfred Königsrainer; Marc André Reymond; Giorgi Nadiradze
Journal:  Pleura Peritoneum       Date:  2021-07-28

9.  Rotational intraperitoneal pressurized aerosol chemotherapy with paclitaxel and cisplatin: pharmacokinetics, tissue concentrations, and toxicities in a pig model.

Authors:  Soo Jin Park; Eun Ji Lee; Aeran Seol; Sunwoo Park; Jiyeon Ham; Ga Won Yim; Seung-Hyuk Shim; Whasun Lim; Suk-Joon Chang; Gwonhwa Song; Ji Won Park; Hee Seung Kim
Journal:  J Gynecol Oncol       Date:  2022-05-24       Impact factor: 4.756

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.